Advertisement
Screener

Cartesian Therapeutics, Inc. (RNAC) Stock Issued During Period, Value, Employee Stock Purchase Plan

Cartesian Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • Cartesian Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-09-30 was $82.00K, a 32.26% increase year-over-year.
  • Cartesian Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-03-31 was $149.00K, a 17.32% increase year-over-year.
  • Cartesian Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2022-09-30 was $62.00K, a 30.34% decline year-over-year.
  • Cartesian Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2022-03-31 was $127.00K, a 76.39% increase year-over-year.
  • Cartesian Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $231.00K, a 22.22% increase from fiscal 2022.
  • Cartesian Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $189.00K, a 17.39% increase from fiscal 2021.
  • Cartesian Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $161.00K, a 12.50% decline from fiscal 2020.
  • Cartesian Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2020 was $184.00K, a 557.14% increase from fiscal 2019.
Period endStock Issued During Period, Value, Employee Stock Purchase Plan 3 monthStock Issued During Period, Value, Employee Stock Purchase Plan 12 month
2023-12-31$231.00K
10-K · filed 2025-03-13
2023-09-30$82.00K
10-Q · filed 2024-11-07
2023-03-31$149.00K
10-Q · filed 2024-11-07
2022-12-31$189.00K
10-K · filed 2024-03-07
2022-09-30$62.00K
10-Q · filed 2023-11-13
2022-03-31$127.00K
10-Q · filed 2023-11-13
2021-12-31$161.00K
10-K · filed 2024-03-07
2021-09-30$89.00K
10-Q · filed 2022-11-03
2021-03-31$72.00K
10-Q · filed 2022-11-03
2020-12-31$184.00K
10-K · filed 2023-03-02
2020-09-30$70.00K
10-Q · filed 2021-11-09
2020-03-31$114.00K
10-Q · filed 2021-11-09
2019-12-31$28.00K
10-K · filed 2022-03-10
2019-09-30$8.00K
10-Q · filed 2020-11-05
2019-03-31$20.00K
10-Q · filed 2020-11-05
2018-12-31$196.00K
10-K · filed 2021-03-12
2018-09-30$145.00K
10-Q · filed 2019-11-08
2018-03-31$51.00K
10-Q · filed 2019-11-08
$231.00K
derived: sum of 4 quarters · filed 2020-03-12
2017-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$180.00K
10-K · filed 2020-03-12
2017-09-30$180.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
2017-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11
2017-03-31$0.00
10-Q · filed 2017-05-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
MACROGENICS INC (MGNX)United States$0.242B-20.11
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23